The biotech industry has been in a slump over the past two years, but Amgen (NASDAQ: AMGN) has performed comparatively well. That's not to say this leading drugmaker hasn't had its share of issues. It has struggled with stiff competition for some of its products and slow revenue growth.
However, the market has faith in Amgen, as evidenced by its rising stock price. Is this faith justified? Let's determine whether buying shares of the biotech giant is worth it.
Source Fool.com